CytomX Therapeutics(CTMX)

Focus: CytomX is a public oncology-focused biotech company specializing in Probodies, a proprietary platform of protease-activated antibodies designed to improve therapeutic selectivity in solid tumors. Founded in 2000 and headquartered in South San Francisco, the company operates as a mid-cap public biotech with 60% R&D intensity.

Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About CytomX Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow CytomX Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$138M

Pipeline & Clinical Trials

CX-904

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT05387265A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Phase 1

Help build intelligence for CytomX Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong revenue growth trajectory: $138M in FY2025 vs. $101M in FY2024 (+37% YoY), demonstrating commercial traction and stability
Proprietary technology platform (Probodies) with broad oncology pipeline provides opportunity to work on differentiated mechanism with multiple shots on goal
Improved profitability: achieved $32M net income in FY2025 vs. -$0.6M loss in FY2024, signaling sustainable business model

Watch Out For

No marketed products yet and all pipeline programs remain in Phase 1-2 stages with zero Phase 3 programs, meaning 5-8+ years before potential revenue from pipeline assets
Zero active job openings reported and no hiring department data visible, suggesting limited near-term expansion or potential structural constraints
Modest cash position of $38M (FY2025) relative to $83M annual R&D spend creates dependency on continued revenue growth and limits runway for unexpected setbacks

Generated by Claude from CytomX Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

CX-188

Solid Tumor, Adult

PHASE_1

Clinical Trials (1)

NCT03706274PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors

Phase 1

CX-2051

Solid Tumor, Adult

PHASE_1

Clinical Trials (1)

NCT06265688First In Human Study of CX-2051 in Advanced Solid Tumors

Phase 1

CX-801

Solid Tumor, Adult

PHASE_1

CX-072

Solid Tumor

PHASE_1_2

Clinical Trials (1)

NCT03013491PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Phase 1/2

CX-2029

Solid Tumor, Adult

PHASE_1_2

Clinical Trials (1)

NCT03543813PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Phase 1/2

CX-2009

Solid Tumor, Adult

PHASE_1_2

Clinical Trials (1)

NCT03149549PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Phase 1/2

CX-072

Solid Tumor

PHASE_2

Clinical Trials (1)

NCT03993379PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Phase 2

CX-2009

Neoplasms

PHASE_2

Clinical Trials (1)

NCT04596150Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2000

Portfolio: 8 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$138M36%

R&D Spend

$83M(60%)7%

Net Income

$32M

Risk Signals

WARN Act Layoff Notices (1)

2025-01-06

46 employees affected— CA

source

Source: state DOL filings, aggregated via Big Local News

No disclosed regulatory warnings, shortages, or layoffs; company appears operationally stable, though early-stage pipeline and modest cash position carry inherent clinical and financial risk.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo